Drugs / C2203
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05814393 Background | Jan 2023 → May 2024 | type 2 diabetes mellitus | JW Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C2203 | “C2203: 25 mg/day for 24 Weeks(PO, BID)” NCT05814393 ↗ |
| Route | Oral | “C2203: 25 mg/day for 24 Weeks(PO, BID)” NCT05814393 ↗ |